Previous 10 | Next 10 |
home / stock / rhhbf / rhhbf news
2024-02-09 02:51:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-02-01 22:52:09 ET Start Time: 09:30 End Time: 11:31 Roche Holding AG (RHHBY) Q4 2023 Earnings Conference Call February 01, 2024, 09:30 AM ET Company Participants Thomas Schinecker - CEO Roche Group Teresa Graham - CEO Roche Pharmaceuticals Matt Sause...
2024-02-01 08:50:59 ET More on Roche Roche: Leveraging Nvidia's AI For Genentech's Innovation Roche Holding Non-GAAP EPS of CHF 18.57, revenue of CHF 58.72B; initiates FY24 outlook Roche ends AC Immune partnership for Alzheimer’s drugs Historical earni...
2024-02-01 03:48:34 ET More on Roche Holding: Roche: Leveraging Nvidia's AI For Genentech's Innovation Roche ends AC Immune partnership for Alzheimer’s drugs Roche, Remix Therapeutics sign license deal Historical earnings data for Roche Holding AG ...
2024-01-22 08:52:21 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune issues updates on Phase 2 studies, cash runway AC Immune Alzheimer's drug advanced into Phase 2b testing Seeking Alpha’s Quant Rating o...
2024-01-19 07:29:39 ET More on Coherus BioSciences Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus ends Junshi-partnered TIGI...
2024-01-18 09:12:34 ET Summary Shares of Tourmaline Bio, Inc. have surged 200% since its public debut in October 2023. The company's main asset, TOUR006, shows potential as a therapy for thyroid eye disease and atherosclerotic cardiovascular disease. Tourmaline is conducting P...
2024-01-16 12:40:46 ET More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation ...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
2024-01-12 13:46:01 ET Summary Pfizer Inc. stock has been on a protracted, yearlong decline due to stronger-than-expected normalization in COVID product uptake rates in 2023. But management's conservative 2024 guidance for COVID product revenues sufficiently de-risks for related h...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...